School of Medicine
Showing 1-10 of 12 Results
Clinical Assistant Professor, Medicine - Hematology
Bio Dr. Iberri is a medical oncologist and hematologist who specializes in the treatment of hematologic malignancies. His clinical practices runs the gamut of malignant and non-malignant hematologic disorders including acute and chronic leukemias, multiple myeloma and lymphomas, and bleeding and thrombotic disorders. He is actively involved in clinical trials evaluating novel agents in hematologic malignancies. His research interests are in the development and application of biomarkers to select patients most likely to benefit from therapy.
Postdoctoral Research Fellow, Pulmonary and Critical Care Medicine
Bio My long-term goal as a physician-scientist is to develop therapeutic strategies for right heart failure by elucidating its pathophysiology.
I graduated from Kyushu University, School of Medicine in Fukuoka, Japan in 2008. Following a residency program at Aso Iizuka Hospital, I finished fellowship in Emergency Medicine (1 year) and Cardiovascular Medicine (2 years). My clinical expertise is general cardiology, cardiac catheterization, echocardiography, and cardiac critical care.
After my clinical training, I started my research career working towards a Ph.D. under the mentorship of Dr. Kensuke Egashira. During my Ph.D., I published two papers focusing on the development of novel therapeutics for acute myocardial infarction and pulmonary arterial hypertension. Through this research experience, I developed skills in modeling and assessing cardiovascular disease in both small (rodents) and large animals (pigs)
In 2017, I was appointed as an Assistant Professor and attending physician in the Department of Emergency and Critical Care Medicine at Kyushu University Hospital. During this period, I learned that right heart failure was one of the most devastating conditions with no treatment options in patients with pulmonary hypertension, congenital heart disease, and patients on long-term mechanical ventricular assist devices. I also continued my research with a research grant funded by the Japanese Society for the Promotion of Science.
In 2019, I decided to further expand my research field into right heart failure and joined Dr. Edda Spiekerkoetter?s lab at Stanford University as a postdoctoral fellow. I am currently focusing on the role of BMPR2 in the cardiomyocytes, the structural changes in the right ventricle under pressure overload, and the development of right ventricle-targeting therapy in pulmonary hypertension.
Postdoctoral Research Fellow, Cardiovascular Medicine
Bio Dr. Ikeda is a physician-scientist who develops innovative diagnostic and therapeutic modalities for patients with cardiovascular disease. Based on his clinical experience as a cardiologist, he has become aware of major clinical shortcomings, specifically in the current pharmaceutical therapies for myocardial infarction (MI) and chronic heart failure (HF). Some evidence-based drug therapies, including ?-blockers, ivabradine, and renin-angiotensin-aldosterone antagonists are difficult to apply to critical patients due to adverse side effects. Drugs that have shown efficacy in basic animal experiments have failed to show significant benefits in clinical trials. To address these problems, he moved to academia to conduct translational research. During his graduate training in the Egashira Lab, he focused on drug delivery systems (DDS) that target mitochondria in animal models of MI. He obtained advanced skills in molecular biology, mitochondrial bioenergetics, and animal surgery. He realized the importance of translational research and the great potential of DDS to overcome many clinical problems. He developed nanoparticle-mediated DDS containing cyclosporine for the treatment of patients with MI. He published a first-author paper and received academic awards for his novel science. Since becoming a postdoctoral fellow in the Yang Lab, he has continued to build upon his previous training in translational research. He is currently developing an innovative therapy, namely, extracellular vesicles-mediated mitochondrial transfer for mitochondria-related diseases such as heart failure and mitochondrial disease.
Program Director (U.S) Japan Biodesign, Stanford Biodesign, Medicine - Med/Cardiovascular Medicine
Bio Program Director (U.S) Japan Biodesign, Stanford Biodesign
Cardiovascular Medicine, Stanford University
Dr. Ikeno is a Research Associate, Cardiovascular Medicine, Stanford University. In this role, he is responsible for pre clinical studies including GLP for medical devices and also regenerative medicines for cardiovascular diseases. Currently, he is devoting himself to the international regulatory project between Japan and the United States, also known as "Harmonization by Doing", whose focus is to collaborate with regulatory agencies such as FDA, PMDA/MHLW, academia and industries for improving the regulatory process in the 2 largest medtech markets. Dr. Ikeno also devoted himself to found Japan biodesign program which is a collaborative program with University of Tokyo, Osaka University, Tohoku University, Japan Federation Medical Device Association, Ministry of Education Japan and Stanford biodesign program. Currently, Dr. Ikeno serves as the Program Director (US) for Japan Biodesign. Dr. Ikeno is co-founder and board member of US-Japan MedTech Frontier which is a non-profit cooperate to make a trans-pacific eco-system of medical device between Japan and USA.
After 9 years clinical practice as an interventional cardiologist and Family Doctor in rural areas of Japan, Dr. Ikeno came to Stanford as a Researcher and completed his Biodesign Certificate Program. Being part of the ecosystem in Silicon Valley, Dr. Ikeno participated in more than 200 medtech projects and 50 GLP studies as well as in the analysis of clinical trials for cardiovascular medicine (BARI2D, FAME, ReOPEN etc). His other academic consortium projects include Peripheral Academic Research Consortium, Global Consensus Working Group of Optical Coherence Tomography, and Japan-US consensus document for the treatment of critical limb ischemia.
Over the last decade, Dr. Ikeno has served as an advisor for medical device industries and currently serves as a chief medical officer of an incubation fund specific for medtech (Medventure Partners, Inc, Tokyo) as a spin-off from Innovation Network Corporation of Japan (INCJ) that is the largest government and private partnership fund in Japan. He is also serving as a chair of cardiovascular working group of APAN (Asian Pacific Advanced Network) that contributes the remote education, research activities, and tele-health using a specialized internet network. Dr.Ikeno is also serving as consulting faculty/lecturer roles in several universities in Japan including University of Tokyo, Osaka University, Tsukuba University etc. Dr. Ikeno has authored over 70 peer reviewed publications and textbooks and has been invited to lecture at international medical conferences. Dr. Ikeno is a council member of U.S.- Japan Council which is a non-profit organization by Japanese American. He is serving as a mentor for START-X MED which is an accelerating program for Stanford related entrepreneurs in medical fields.
Falk CVRC CV007
300 Pasteur Drive
Palo Alto, CA 94305-5406
John P.A. Ioannidis
Professor of Medicine (Stanford Prevention Research), of Epidemiology and Population Health and by courtesy, of Statistics and of Biomedical Data Science
Current Research and Scholarly Interests Meta-research
Clinical and molecular epidemiology
Human genome epidemiology
Reporting of research
Empirical evaluation of bias in research
Statistical methods and modeling
Meta-analysis and large-scale evidence
Prognosis, predictive, personalized, precision medicine and health
Sociology of science
Clinical Associate Professor, Medicine - Primary Care and Population Health
Current Research and Scholarly Interests My research interests include the use and abuse of anabolic steroids and other performance enhancing/cognitive enhacing drugs.
Assistant Professor of Medicine (Oncology)
Bio Dr. Itakura is an Assistant Professor of Medicine (Oncology) in the Stanford University School of Medicine and practicing oncologist at the Stanford Cancer Center with background in biomedical informatics. She is a physician-scientist whose research mission is to drive medical advances at the intersection of cancer and data science research. Specifically, she aims to innovate state-of-the-art technologies to extract clinically useful knowledge from heterogeneous multi-scale biomedical data to improve diagnostics and therapeutics in cancer. She is a board-certified hematologist-oncologist and informaticist with specialized training in basic science, health services, and translational research. Her clinical background in oncology and PhD training in Biomedical Informatics position her to develop and apply data science methodologies on heterogeneous, multi-scale cancer data to extract actionable knowledge that can improve patient outcomes. Her ongoing research to develop and apply cutting-edge knowledge and skills to pioneer new robust methodologies for analyzing cancer big data is being supported by an NIH K01 Career Development Award in Biomedical Big Data Science. Her research focuses on developing and applying machine learning frameworks and radiogenomic approaches for the integrative analysis of heterogeneous, multi-scale data to accelerate discoveries in cancer diagnostics and therapeutics. Projects include prediction modeling of survival and treatment response, biomarker discovery, cancer subtype discovery, and identification of new therapeutic targets.